Quarterly report pursuant to Section 13 or 15(d)

Agreements with Incyte Corporation - Collaboration Agreement (Details)

v3.19.1
Agreements with Incyte Corporation - Collaboration Agreement (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Jan. 08, 2018
Jan. 31, 2018
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Deferred revenue recognized     $ 500 $ 400  
Deferred revenue          
Deferred revenue     9,748   $ 10,202
Deferred revenue, current     1,800    
Deferred revenue, long-term     $ 7,900   $ 8,276
Incyte | Collaboration Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Up-front consideration   $ 10,000      
Up-front consideration, cash   2,500      
Up-front consideration, pre-paid research funding   $ 7,500      
Maximum target selection milestone payments and option exercise fees the Company is eligible to receive $ 54,000        
Maximum development and regulatory milestone payments the Company is eligible to receive for each of the validated targets 50,000        
Maximum commercial milestone payments the Company is eligible to receive for each of the validated targets if products arising from collaboration are approved $ 65,000        
Period of written notice to terminate the agreement by Incyte 60 days        
Period of written notice to terminate the agreement by the Company in the event the counterparty or one of its affiliates or sublicenses challenges the validity or enforceability of certain patent rights controlled by the Company 30 days        
Period of written notice to terminate the agreement by either of the parties in the event of an uncured material breach of the collaboration agreement by the other party 30 days        
Total transaction price $ 12,300        
Upfront non-refundable and non-creditable payment 2,500        
Prepaid research amount 7,500        
Premium paid on equity investment $ 2,300